A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteins
Daniel J. Kelpsch, Liyun Zhang, James H. Thierer, Adrian G. Rivera Cruz, Kobe Koren, Urmi Kumar, Yuki Lin, Monica R. Hensley, Mira Sohn, Jun O. Liu, Thomas Lectka, Jeff S. Mumm, Steven Arthur Farber
A zebrafish phenotypic drug screen identifies 49 ApoB-lowering compounds, with enoxolone showing efficacy dependent on HNF4 function, validating the LipoGlo platform for B-lp modulation.
eLife · Aug 27, 2026Peer-reviewedPhysiology